Opus Genetics completes dosing in first cohort of Leber congenital amaurosis trial
Dosing is complete in the first cohort of the phase 1/2 clinical trial of OPGx-LCA5 for the treatment of Leber congenital amaurosis, according to a press release from Opus Genetics.